Prostate specific antigen only progression of prostate cancer

Journal of Urology

Volumn 163, Issue 6, 2000, Pages 1632-1642

  Moul, Judd W ^a,b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c Center for Prostate Disease Research   (United States)

Author keywords

Prostate; Prostate specific antigen; Prostatic neoplasms; Recurrence

Indexed keywords

CAPROMAB PENDETIDE IN 111; PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; HUMAN; MALE; MEDICAL DECISION MAKING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034039983     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67511-8     Document Type: Review

References (137)

1. Landis, S. H., Murray, T., Bolden, S. et al: Cancer statistics, 1999. CA Cancer J Clin, 49: 8, 1999
2. Stephenson, R. A: Population-based prostate cancer trends in the PSA era: data from the Surveillance, Epidemiology, and End Results (SEER) Program. 1998 Monogr Urol, 19: 3, 1998
3. Moul, J. W.: Treatment options for prostate cancer: part 1-stage, grade, PSA, and changes in the 1990s. Am J Manag Care, 4: 1031, 1998
4. Polascik, T. J., Oesterling, J. E. and Partin, A. W.: Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol, 162: 293, 1999
5. Yu, H., Diamandis, E. P., Prestigiacomo, A. F. et al: Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem, 41: 430, 1995
6. Pound, C. R., Partin, A. W., Epstein, J. I. et al: Prostate-specific antigen following anatomical radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am, 24: 395, 1997
7. Partin, A. W., Pearson, J. D., Landis, P. K. et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 43: 649, 1994
8. Waxman, S., Stevens, A. K., Walsh, R. A. et al: Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Oncology (Huntingt), 11: 457, 1997
9. Forman, J. D. and Velasco, J.: Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology (Huntingt), 12: 33, 1998
10. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys, 37: 1035, 1997
11. Shipley, W. U., Thames, H. D., Sandler, H. M. et al: Radiation therapy for clinically localized prostate cancer: a multiinstitutional pooled analysis. JAMA, 281: 1598, 1999
12. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathologic findings with progression after radical prostatectomy. Cancer, 71: 3582, 1993
13. Norberg, M., Holberg, L., Wheeler, T. et al: Five year follow-up after radical prostatectomy for localized prostate cancer: a study of the impact of different tumor variables on progression. Scand J Urol Nephrol, 28: 391, 1994
14. Ravery, V., Boccon-Gibod, L. A., Meulemans, A. et al: Predictive value of pathological features for progression after radical prostatectomy. Eur Urol, 26: 197, 1994.
15. D'Amico, A. V., Whittington, R., Malkowicz, S. B. et al: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol, 154: 131, 1995
16. Partin, A. W., Piantadosi, S. and Marshall, F. F.: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 45: 831, 1995
17. Lerner, S. E., Blute, M. L., Bergstralh, E. J. et al: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol, 156: 137, 1996
18. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K. et al: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol, 156: 1511, 1996
19. Bettencourt, M. C., Bauer, J. J., Sesterhenn, I. A. et al: Ki-67 expression is a prognostic marker of recurrence after radical prostatectomy. J Urol, 156: 1064, 1996
20. Bauer, J. J., Connelly, R. R., Sesterhenn, I. A. et al: Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer, 79: 952, 1997
21. Isaacs, J. T.: Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol, 150: 1511, 1997
22. Bostwick, D. G.: Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens. Anal Quant Cytol Histol, 20: 323, 1998
23. Moul, J. W., Connelly, R. R., Perahia, B. et al: The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol, 159: 935, 1998
24. Bauer, J. J., Connelly, R. R., Sesterhenn, I. A. et al: Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol, 159: 929, 1998
25. Bettencourt, M.-C., Bauer, J. J., Sesterhenn, I. A. et al: CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol, 160: 459, 1998
26. K1P1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst, 90: 1284, 1998
27. Kattan, M. W., Eastham, J. A., Stapleton, A. M. et al: a preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90: 766, 1998
28. D'Amico, A. V., Whittington, R., Malkowicz, S. B. et al: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol, 17: 168, 1999
29. Vollmer, R. T., Keetch, D. W. and Humphrey, P. A.: Predicting the pathology results of radical prostatectomy from preoperative information: a validation study. Cancer, 83: 1567, 1998
30. Terris, M. K., Klonecke, A. S., McDougall, I. R. et al: Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med, 32: 1713, 1991
31. Cher, M. L., Bianco, F. J., Jr., Lam, J. S. et al: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol, 160: 1387, 1998
32. Johnstone, P. A. S., Tarman, G. J., Riffenburgh, R. et al: Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol Oncol, 3: 108, 1997
33. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol, 152: 1490, 1994
34. Kahn, D., Haseman, M., Libertino, J. et al: Indium-111 capromab pendetide (ProstaScint) imaging of patients with rising PSA post-prostatectomy. J Urol, suppl., 157: 204, abstract 795, 1997
35. Levesque, P. E., Nieh, P. T., Zinman, L. N. et al: Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology, 51: 978, 1998
36. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol, 159: 2041, 1998
37. Petronis, J. D., Regan, F. and Lin, K.: Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med, 23: 672, 1998
38. Kahn, D., Williams, R. D. and Haseman, M. K.: Radioimmunoscintigraphy with In-111 labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol, 16: 284, 1998
39. Hinkle, G. H., Burgers J. K., Neal, C. E. et al: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer, 83: 739, 1998
40. Elgamal, A. A., Troychak, M. J. and Murphy, G. P.: ProstaScint scan may enhance identification of prostate cancer recurrence after prostatectomy, radiation, or hormonal therapy: analysis of 136 scans of 100 patients. Prostate, 37: 261, 1998
41. Burgers, J. K., Hinkle, G. H. and Haseman, M. K.: Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol, 13: 103, 1995
42. Saitoh, H., Yoshida, K.-I., Uchijima, Y. et al: Two different lymph node metastatic patterns of a prostatic cancer. Cancer, 65: 1843, 1990
43. Foster, L. S., Jajodia, P., Fournier, G., Jr. et al: The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol, 149: 1024, 1993
44. Fowler, J. E., Jr., Brooks, J., Pandey, P. et al: Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol, 153: 1011, 1995
45. Crook, J. M., Perry, G. A., Robertson, S. et al: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology, 45: 624, 1995
46. Svetec, D., McCabe, K., Peretsman, S. et al: Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol, 159: 1606, 1998
47. Cox, J. D., Gallagher, M. J., Hammond, E. H. et al: Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol, 17: 1155, 1999
48. Connolly, J. A., Shinohara, K., Presti, J. C., Jr. et al: Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology, 47: 225, 1996
49. Hudson, M. A. and Catalona, W. J.: Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. J Urol, 143: 1174, 1990
50. Link, P., Freiha, F. S. and Stamey, T. A.: Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol, 145: 532, 1991
51. Kaplan, I. D. and Bagshaw, M. A.: Serum prostate-specific antigen after post-prostatectomy radiotherapy. Urology, 39: 401, 1992
52. McCarthy, J. F., Catalona, W. J. and Hudson, M. A.: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol, 151: 1575, 1994
53. Wu, J. J., King, S. C., Montana, G. S. et al: The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys, 32: 317, 1995
54. Haab, F., Meulemans, A., Boccon-Gibod, L. et al: Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology, 45: 1022, 1995
55. Schild, S. C., Buskirk, S. J., Wong, W. W. et al: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol, 156: 1725, 1996
56. Medini, E., Medini, I., Reddy, P. K. et al: Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer, 78: 1254, 1996
57. Coetzee, L. J., Hars, V. and Paulson, D. F.: Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology, 47: 232, 1996
58. Forman, J. D., Meetze, K., Pontes, E. et al: Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol, 158: 1436, 1997
59. Morris, M. M., Dallow, K. C., Zeitman, A. L. et al: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys, 38: 731, 1997
60. Cadeddu, J. A., Partin, A. W., DeWeese, T. L. et al: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol, 159: 173, 1998
61. Garg, M. K., Tekyi-Mensah, S., Bolton, S. et al: Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology, 51: 998, 1998
62. Raymond, J. F., Vuong, M. and Russell, K. J.: Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys, 41: 93, 1998
63. Valicenti, R. K., Gomella, L. G., Ismail, M. et al: Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma: effect of early adjuvant radiation therapy on biochemical control. Cancer, 82: 1909, 1998
64. Egawa, S., Matsumoto, K., Suyama, K. et al: Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology, 53: 148, 1999
65. Vicini, F. A., Ziaja, E. L., Kestin, L. L. et al: Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology, 54: 111, 1999
66. Carson, C. C., III, Zincke, H., Utz, D. C. et al: Radical prostatectomy after radiotherapy for prostatic cancer. J Urol, 124: 237, 1980
67. Thompson, I. M., Rounder, J. B., Spence, C. R. et al: Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer, 61: 1464, 1988
68. Neerhut, G. J., Wheeler, T., Cantini, M. et al: Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol, 140: 544, 1988
69. Link, P. and Freiha, F. S.: Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology, 37: 189, 1991
70. Moul, J. W. and Paulson, D. F.: The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer, 68: 1265, 1991
71. Ahlering, T. E., Lieskovsky, G. and Skinner, D. G.: Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol, 147: 900, 1992
72. Pontes, J. E., Montie, J. E., Klein, E. J. et al: Salvage surgery for radiation failure in prostate cancer. Cancer, 71: 976, 1993
73. Stein, A., Smith, R. B. and deKernion, J. B.: Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology, 40: 197, 1992
74. Lerner, S. E., Blute, M. L. and Zincke, H.: Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol, 154: 1103, 1995
75. Rogers, E., Ohori, M., Kassabian, V. S. et al: Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol, 153: 104, 1995
76. Garzotto, M. and Wajsman, Z.: Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol, 159: 950, 1998
77. Gheiler, E. L., Tefilli, M. V., Tiguert, R. et al: Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 51: 789, 1998
78. Moul, J. W.: Editorial comment. J Urol, 159: 954, 1998
79. Onik, G. M., Cohen, J. K., Reyes, G. D. et al: Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer, 72: 1291, 1993
80. Coogan, C. L. and McKiel, C. F.: Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. J Urol, 154: 1813, 1995
81. Wieder, J., Schmidt, J. D., Casola, G. et al: Transrectal ultrasound-guided transperineal cryoablation in the treatment of prostate carcinoma: preliminary results. J Urol, 154: 435, 1995
82. Bales, G. T., Williams, M. J., Sinner, M. et al: Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology, 46: 676, 1995
83. Miller, R. J., Jr., Cohen, J. K., Shuman, B. et al: Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post-radiation recurrence of adenocarcinoma. Cancer, 77: 1510, 1996
84. Shinohara, K., Connolly, J. A., Presti, J. C., Jr. et al: Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. J Urol, 156: 115, 1996
85. Pisters, L. L., von Eschenbach, A. C., Scott, S. M. et al: The efficacy and complications of salvage cryotherapy of the prostate. J Urol, 157: 921, 1997
86. Cespedes, R. D., Pisters, L. L., von Eschenbach, A. C. et al: Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients. J Urol, 157: 237, 1997
87. Perrotte, P., Litwin, M. S., McGuire, E. J. et al: Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol, 162: 398, 1999
88. Lee, F., Bahn, D. K., McHugh, T. A. et al: Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring-a one year follow-up. Anticancer Res, 17: 1511, 1997
89. Grado, G. L., Collins, J. M., Kriegshauser, J. S. et al: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology, 53: 2, 1999
90. Parker, C. C. and Dearnaley. D. P.: The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol, 49: 103, 1998
91. Wallner, K. E., Nori, D., Morse, M. J. et al: 125 iodine reimplantation for locally progressive prostatic carcinoma. J Urol, 144: 704, 1990
92. Loening, S. A. and Turner, J. W.: Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate, 23: 283, 1993
93. Moul, J. W.: Contemporary hormonal management of advanced prostate cancer. Oncology (Huntingt), 12: 499, 1998
94. Moul, J. W.: A better definition of advanced prostate cancer for today's patients. Contemp Urol, 9: 15, 1997
95. Ziada, A. M. and Crawford, E. D.: Advanced prostate cancer. Prostate Cancer Prostate Dis, 2: 21-26, 1999.
96. Cox, R. L. and Crawford, E. D.: Estrogens in the treatment of prostate cancer. J Urol, 154: 1991, 1995
97. Labrie, F., Dupont, A., Belanger, A. et al: Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem, 23: 833, 1985
98. Janknegt, R. A., Abbou, C. C., Bartoletti, R. et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol, 149: 77, 1993
99. Eisenberger, M. A., Crawford, E. D., Wolf, M. et al: Prognostic factors in stage D2 prostate cancer, important implications for future trials: results of a cooperative intergroup study (INT .0036). Semin Oncol, 21: 613, 1994
100. Crawford, E. D., Eisenberger, M. A., McLeod, D. G. et al: A controlled trial of leuprolide with and without flutamide in prostate cancer. N Engl J Med, 321: 419, 1989
101. Denis, L. J., Carnelro de Moura, J. L., Bono, A. et al: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC Trial (30853). Urology, 42: 119, 1993
102. Schellhammer, P. F., Sharifi, R., Block, N. L. et al: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized multicenter trial. Urology, 50: 330, 1997
103. Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D. et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med, 339: 1036, 1998
104. Bertagna, C., De Gery, A., Huchner, M. et al: Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostate cancer. A meta-analysis of seven randomized, double-blind trials (1056 patients). Br J Urol, 73: 396, 1994
105. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet, 346: 265, 1995
106. Caubet, J. F., Tosteson, T. D., Dong, E. W. et al: Maximum androgen blockade in advanced prostate cancer: a metaanalysis of published randomized controlled trials using non-steroidal antiandrogens. Urology, 49: 71, 1997
107. Bennett, C. L., Tosteson, T. D., Schmitt, B. et al: Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostate Dis, 2: 4, 1999
108. McLeod, D. G., Crawford, E. D. and DeAntoni, E. P.: Combined androgen blockade: the gold standard for metastatic prostate cancer. Eur Urol, suppl., 32: 70, 1997.
109. Denis, L. J., Keuppens, F., Smith, P. H. et al: Maximal androgen blockade: final analysis of EORTC Phase III Trial 30853. Eur Urol, 33: 144, 1998
110. The Medical Research Council Prostate Cancer Working Party Investigators Group.: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol, 79: 235, 1997
111. Messing, E., Manola, J., Wilding, G. et al: Immediate hormonal therapy vs. observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: a randomized Phase III Eastern Cooperative Oncology Group/Inter Group trial. J Urol, suppl., 161: 175, abstract 673, 1999
112. Schroder, F. H.: Endocrine treatment of prostate cancer-recent developments and the future. Part I: maximal androgen blockade, early vs. delayed endocrine treatment and side-effects. BJU Int, 83: 161, 1999
113. Klotz, L. H., Herr, H. W., Morse, M. J. et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer, 58: 2546, 1986
114. Goldenberg, S. L., Bruchovsky, N., Gleave, M. E. et al: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology, 45: 839, 1995
115. Higano, C. S., Ellis, W., Russell, K. et al: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology, 48: 800, 1996
116. Tunn, U. W.: Intermittent endocrine therapy of prostate cancer. Eur Urol, suppl., 30: 22, 1996
117. Oliver, R. T., Williams, G., Paris, A. M. et al.: Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology, 49: 79, 1997
118. Grossfeld, G. D., Small, E. J. and Carroll, P. R.: Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology, 51: 137, 1998
119. Horwich, A., Huddart, R. A., Gadd, J. et al: A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol, 81: 96, 1998
120. Gleave, M., Bruchovsky, N., Goldenberg, S. L. et al: Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol, suppl., 34: 37, 1998
121. Kurek, R., Renneberg, H., Lubben, G. et al: Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol, suppl., 35: 27, 1999
122. Gleave, M., Goldenberg, S. L., Bruchovsky, N. et al: Review: Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostate Dis, 1: 289, 1998
123. Andriole, G., Lieber, M., Smith, J. et al: Treatment with finasteride following radical prostatectomy for prostate cancer. Urology, 45: 491, 1995
124. Fleshner, N. E. and Trachtenberg, J.: Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol, 154: 1642, 1995
125. Fleshner, N. E. and Fair, W. R.: Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol, 78: 907, 1996
126. Ornstein, D. K., Rao, G. S., Johnson, B. et al: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology, 48: 901, 1996
127. Brufsky, A., Fontaine-Rothe, P., Berlane, K. et al: Finasteride and flutamide as potency-sparing androgen-ablative therapy for advance adenocarcinoma of the prostate. Urology, 49: 913, 1997
128. Sandhu, S. S., Matveev, V. B. and Kaisary, A. V.: Finasteride plus flutamide for prostatic carcinoma. Br J Urol, 80: 360, 1997
129. Harding, P., Moul, J. W. and McLeod, D. G.: Combination flutamide and finasteride in PSA-only recurrence after prior local prostate cancer therapy. J Urol, suppl., 159: 130, abstract 491, 1998
130. Tsukamoto, S., Akaza, H., Onozawa, M. et al: A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic carcinoma to macroscopic carcinoma in rats. Cancer, 82: 531, 1998
131. Brooks, J. R., Berman, C., Nguyen, H. et al: Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate, 18: 215, 1991
132. Schroder, F. H.: Antiandrogens as monotherapy for prostate cancer. Eur Urol, suppl., 34: 12, 1998
133. Fleshner, N. E. and Trachtenberg, J.: Sequential androgen blockade: a biological study in the inhibition of prostatic growth. J Urol, 148: 1928, 1992
134. Fleshner, N. E. and Trachtenberg, J.: Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol, suppl., 24: 106, 1993
135. Lisle, T., Mackenzie, S., Ziada, A. et al: Androgen deprivation therapy using finasteride and low dose flutamide to treat PSA failure following therapy for clinically localized adenocarcinoma of the prostate (CaP). J Urol, 161 (suppl. 4): 299 (abstract #1151), 1999.
136. Pound, C. R., Partin, A. W., Eisenberger, M. A. et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
137. Scher, H. I.: Management of prostate cancer after prostatectomy: treating the patient, not the PSA. JAMA, 281: 1642, 1999